{
    "medicine_id": "e06b7879097876ae48b3c27b34f78d2dc7dfa57b",
    "platform_id": "1260",
    "metadata": {
        "name": "PREZISTA 100 mg ml oral suspension",
        "composition": "Each ml of oral suspension contains 100 mg of darunavir as ethanolate",
        "clinical_particulars": {
            "therapeutic_indications": "PREZISTA co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus HIV 1 infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight see section 4 2 PREZISTA co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus HIV 1 infection in adults and adolescents aged 12 years and older weighing at least 40 kg see section 4 2 In deciding to initiate treatment with PREZISTA co administered with cobicistat or low dose ritonavir careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents Genotypic or phenotypic testing when available and treatment history should guide the use of PREZISTA see sections 4 2 4 4 and 5 1",
            "contraindications": {
                "disease": "Hypersensitivity to the active substance or to any of the excipients listed in section 6 1 Patients with severe Child Pugh Class C hepatic impairment Concomitant treatment with any of the following medicinal products given the expected decrease in plasma concentrations of darunavir ritonavir and cobicistat and the potential for loss of therapeutic effect see sections 4 4 and 4 5 Applicable to darunavir boosted with either ritonavir or cobicistat The combination product lopinavir ritonavir see section 4 5 Hypericum perforatum Co administration is expected to reduce plasma concentrations of darunavir ritonavir and cobicistat which could lead to loss of therapeutic effect and possible development of resistance see sections 4 4 and 4 5 Applicable to darunavir boosted with cobicistat not when boosted with ritonavir Darunavir boosted with cobicistat is more sensitive for CYP3A induction than darunavir boosted with ritonavir Concomitant use with strong CYP3A inducers is contraindicated since these may reduce the exposure to cobicistat and darunavir leading to loss of therapeutic effect Strong CYP3A inducers include e g carbamazepine phenobarbital and phenytoin see sections 4 4 and 4 5 Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that are highly dependent on CYP3A for clearance which results in increased exposure to the co administered medicinal product Therefore concomitant treatment with such medicinal products for which elevated plasma concentrations are associated with serious and or life threatening events is contraindicated applies to darunavir boosted with either ritonavir or cobicistat These active substances include e g alfuzosin amiodarone bepridil dronedarone ivabradine quinidine ranolazine astemizole terfenadine colchicine when used in patients with renal and or hepatic impairment see section 4 5 ergot derivatives e g dihydroergotamine ergometrine ergotamine methylergonovine elbasvir grazoprevir cisapride dapoxetine domperidone naloxegol lurasidone pimozide quetiapine sertindole see section 4 5 triazolam midazolam administered orally for caution on parenterally administered midazolam see section 4 5 sildenafil when used for the treatment of pulmonary arterial hypertension avanafil simvastatin lovastatin lomitapide see section 4 5 dabigatran ticagrelor see section 4 5",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Hydroxypropyl cellulose;Microcrystalline cellulose;Carmellose sodium;Citric acid monohydrate;Sucralose;Strawberry cream flavour;Masking flavour;Sodium methyl parahydroxybenzoate (E219);Hydrochloric acid (for pH adjustment);Purified water",
                "incompatibilities": "Not applicable."
            }
        },
        "revision_date": "2022-09-30"
    }
}